CRSP ファイナンス： CRISPR Therapeutics AG AI分析

ホーム

株式

CRSP

財務状況

CRSP 財務

CRISPR Therapeutics AG

$49.54

1.55%

$0.75

終値： Apr 02, 16:00:00 GMT-4

$49.51

-0.06%

$-0.03

アフターマーケット：Apr 02, 20:00:00 GMT-4

概要予測収入配当財務状況

主要データ

前終値

$48.78

始値

$47.3

当日レンジ

$47.13 - $49.8

52週レンジ

$30.04 - $78.48

取引高

1.7M

平均取引高

1.9M

配当利回り

1株当たり利益(TTM)

-6.51

時価総額

$4.7B

CRSPとは何ですか？

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. The company is headquartered in Zug, Zug. The company went IPO on 2016-10-19. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The firm aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The firm has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The firm product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.

特徴

リソース

市場

収入

貸借対照表

現金の流れ

年次

四半期

CRSP 収入

金額は百万米ドル単位。会計年度は2月から1月まで。

Breakdown	TTM	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021
収入	3	3	37	371	1	915
収益成長率（YoY）	-92%	-92%	-90%	37,000%	-100%	--
収益のコスト	--	--	--	--	--	--
売上総利益	--	--	--	--	--	--
販売、一般および管理	287	287	183	206	212	102
研究開発	284	284	320	387	461	438
運営費用	571	571	503	593	674	541
その他の非営業収入（費用）	86	86	103	71	22	6
税引前利益	-577	-577	-362	-150	-650	379
所得税費	3	3	3	2	0	1
純利益	-581	-581	-366	-153	-650	377
純利益成長率	59%	59%	139%	-76%	-272%	-208%
流通済み株式数（希薄化後）	95.32	89.92	84.35	79.22	77.7	80.4
株式変動（前年比）	12%	7%	6%	2%	-3%	22%
EPS（希薄化）	-6.1	-6.46	-4.34	-1.93	-8.36	4.7
EPS成長率	43%	49%	124%	-77%	-278%	-189%
フリーキャッシュフロー	-370	-370	-144	-272	-532	457
1株当たりフリーキャッシュフロー	--	--	--	--	--	--
粗利益	--	--	--	--	--	--
営業利益率	-18,933.33%	-18,933.33%	-1,259.45%	-59.83%	-67,300%	40.76%
利益率	-19,366.66%	-19,366.66%	-989.18%	-41.23%	-65,000%	41.2%
フリーキャッシュフロー利益率	-12,333.33%	-12,333.33%	-389.18%	-73.31%	-53,200%	49.94%
EBITDA	-549	-549	-447	-203	-649	391
EBITDAマージン	-18,300%	-18,300%	-1,208.1%	-54.71%	-64,900%	42.73%
D&A による EBITDA	19	19	19	19	24	18
営業利益	-568	-568	-466	-222	-673	373
営業利益率	-18,933.33%	-18,933.33%	-1,259.45%	-59.83%	-67,300%	40.76%
実効税率	-0.51%	-0.51%	-0.82%	-1.33%	0%	0.26%

Follow-Up Questions

CRISPR Therapeutics AG'in temel mali tabloları nelerdir?



Son mali tabloya (Form-10K) göre, CRISPR Therapeutics AG'in toplam varlıkları $2,265 olup, net 損失 $-581'dir.

CRSP'ün temel finansal oranları nelerdir?



CRISPR Therapeutics AG'in cari oranı 6.6, net kâr marjı -19,366.66, hisse başına satış $0.03'dir.

CRISPR Therapeutics AG'in geliri segment veya coğrafya bazında nasıl dağılıyor?



CRISPR Therapeutics AG の最大収益セグメントは Genome-editing Technology で、最新の利益発表における収益は 37,314,000 です。地域別に見ると、Switzerland and United States が CRISPR Therapeutics AG の主要市場であり、収益は 37,314,000 です。

CRISPR Therapeutics AG kârlı mı?



いいえ, son mali tablolara göre CRISPR Therapeutics AG'in net 損失 $-581'dir.

CRISPR Therapeutics AG'in herhangi bir yükümlülüğü var mı?



はい, CRISPR Therapeutics AG'in yükümlülüğü 343'dir.

CRISPR Therapeutics AG'in tedavüldeki hisse sayısı kaçtır?



CRISPR Therapeutics AG'in toplam tedavüldeki hisse sayısı 95.89'dir.

CRISPR Therapeutics AG (CRSP) 財務

CRSP 株価推移チャート